Iterum Therapeutics plc (ITRM)

USD 1.1

(4.76%)

Market Cap (In USD)

38.03 Million

Revenue (In USD)

-

Net Income (In USD)

-38.37 Million

Avg. Volume

409.22 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.808-3.02
PE
-0.87
EPS
-1.26
Beta Value
2.248
ISIN
IE000TTOOBX0
CUSIP
G6333L101
CIK
1659323
Shares
34581400.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Corey N. Fishman
Employee Count
-
Website
https://www.iterumtx.com
Ipo Date
2018-05-25
Details
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.